Antonio C Wolff

Professor

1994 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Antonio C Wolff is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 6 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

DNA methylation markers predict recurrence-free interval in triple-negative breast cancer

Fackler, M. J., Cho, S., Cope, L., Gabrielson, E., Visvanathan, K., Wilsbach, K., Meir-Levi, D., Lynch, C. F., Marks, J., Geradts, J., Regan, M. M., Viale, G., Wolff, A. C., Sukumar, S. & Umbricht, C. B., Dec 1 2020, In : npj Breast Cancer. 6, 1, 3.

Research output: Contribution to journalArticle

Open Access
  • Evaluation of the predictive role of tumor immune infiltrate in patients with HER2-positive breast cancer treated with neoadjuvant anti-HER2 therapy without chemotherapy

    de Angelis, C., Nagi, C., Hoyt, C. C., Liu, L., Roman, K., Wang, C., Zheng, Y., Veeraraghavan, J., Sethunath, V., Nuciforo, P., Wang, T., Tsimelzon, A., Mao, S., Hilsenbeck, S. G., Trivedi, M. V., Cataldo, M. L., Pavlick, A., Wolff, A. C., Weigelt, B., Reis-Filho, J. S. & 5 others, Prat, A., Gutierrez, C., Osborne, C. K., Rimawi, M. F. & Schiff, R., Feb 1 2020, In : Clinical Cancer Research. 26, 3, p. 738-745 8 p.

    Research output: Contribution to journalArticle

  • TBCRC023: A randomized phase II neoadjuvant trial of lapatinib plus trastuzumab without chemotherapy for 12 versus 24 weeks in patients with HER2-positive breast cancer

    on behalf of the Translational Breast Cancer Research Consortium, Feb 15 2020, In : Clinical Cancer Research. 26, 4, p. 821-827 7 p.

    Research output: Contribution to journalArticle

  • Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients

    Lambertini, M., Campbell, C., Bines, J., Korde, L. A., Izquierdo, M., Fumagalli, D., Del Mastro, L., Ignatiadis, M., Pritchard, K., Wolff, A. C., Jackisch, C., Lang, I., Untch, M., Smith, I., Boyle, F., Xu, B., Barrios, C. H., Baselga, J., Moreno-Aspitia, A., Piccart, M. & 2 others, Gelber, R. D. & de Azambuja, E., Jan 1 2019, In : Journal of the National Cancer Institute. 111, 1, p. 86-94 9 p.

    Research output: Contribution to journalArticle

  • A phase II randomized study of neoadjuvant letrozole plus alpelisib for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (NeO-ORB)

    Mayer, I. A., Prat, A., Egle, D., Blau, S., Alejandro Perez Fidalgo, J., Gnant, M., Fasching, P. A., Colleoni, M., Wolff, A. C., Winer, E. P., Singer, C. F., Hurvitz, S., Estevez, L. G., Van Dam, P. A., Kummel, S., Mundhenke, C., Holmes, F., Babbar, N., Charbonnier, L., Diaz-Padilla, I. & 3 others, Vogl, F. D., Sellami, D. & Arteaga, C. L., Jan 1 2019, In : Clinical Cancer Research. 25, 10, p. 2975-2987 13 p.

    Research output: Contribution to journalArticle

    Open Access